<DOC>
	<DOCNO>NCT02503150</DOCNO>
	<brief_summary>This trial compare efficacy safety modify FOLFOX6 [ mFOLFOX6 , specific chemotherapy regimen Oxaliplatin ,5-Fluorouracil Leucovorin ] chemotherapy plus Antigen Pulsed Dendritic Cells ( APDC，a kind autologous tumor lysates pulse human dendritic cell vaccine ) modify chemotherapy alone patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Trial Antigen Pulsed Dendritic Cells ( APDC ) Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Metastatic colorectal cancer ( CRC ) patient randomly assign ( 3:1 ) receive either modify FOLFOX6 [ mFOLFOX6 ] chemotherapy combine Antigen Pulsed Dendritic Cells ( Arm APDC + Chemotherapy ) , chemotherapy alone ( Arm Chemotherapy ) . Each patient recruit study receive maximum 12 cycle ( 14 days/cycle ) mFOLFOX6 chemotherapy . Patients Arm APDC + Chemotherapy receive APDC vaccination addition chemotherapy cycle 1-3 7-9 , cycle 4-6 10-12 receive chemotherapy . APDC + Chemotherapy Chemotherapy stop case disease progression , intolerable toxicity , patient withdrawal consent . After 12 cycle , patient Arm APDC + Chemotherapy receive 5-Fluorouracil treatment plus every 3 month APDC therapy patient Arm Chemotherapy receive 5-Fluorouracil treatment . PFS , ORR OS assess , toxicity immunologic effect monitor .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma colorectum metastatic lesion receive previous therapy metastatic lesion ; 2 . Be able undergo surgical resection obtain least 1cm3 tumor tissue ; 3 . The patient 1875 year old regardless gender ; 4 . An estimated life expectancy 6 month ECOG≤2 ; 5 . Adequate hepatic , renal , bone marrow function : neutrophilic granulocyte≥1.5×109/L , Hb ( hemoglobin ) ≥90g/L , PLT ( platelet ) ≥100×109/L , serum Cr ( creatinine ) ≤1.5time upper normal limit , serum TBIL ( total bilirubin ) ≤1.5time upper normal limit , serum ALT AST ( alanine aminotransferase aspartate aminotransferase ) ≤2.5time upper normal limit , hepatic metastasis CRC patient ' serum ALT/AST≤5time upper normal limit ; 6 . At least one measurable lesion surgical resection ( According standard RECIST1.1 version : Response Evaluation Criteria Solid Tumors 1.1 version ) ; 7 . Written informed consent . 1 . Severe ( ie , active ) heart disease , coronary heart disease symptom , New York Heart Association ( NYHA ) IIclass serious congestive heart failure severe arrhythmia require medication intervention , history myocardial infarction within last 12 month ; severe pulmonary dysfunction ; peripheral neuropathy ; unstable hypertension ; 2 . Metastases lesion &gt; 50 % liver volume ; 3 . Autoimmune diseases , organ transplantation require immunosuppressive therapy patient require longterm systemic corticosteroid therapy ; 4 . History malignant disease ( except cure basal cell carcinoma cervical carcinoma situ ) last 5 year ; 5 . Pregnant lactate woman ( woman childbearing age baseline pregnancy test positive pregnancy test examine . Menopausal woman menopause least 12 month ) ; 6 . Acute chronic infectious disease active phase ; severe uncontrolled infection , serious uncontrolled concomitant disease ; 7 . Definite history allergy allergic constitution ; 8 . Chemotherapy , radiotherapy immunotherapy within four week ; 9 . Administration investigational drug procedure within four week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Tumor Therapeutic Vaccine</keyword>
	<keyword>Dendritic Cell</keyword>
</DOC>